JP2002504902A - 抗腫瘍治療剤 - Google Patents
抗腫瘍治療剤Info
- Publication number
- JP2002504902A JP2002504902A JP50129599A JP50129599A JP2002504902A JP 2002504902 A JP2002504902 A JP 2002504902A JP 50129599 A JP50129599 A JP 50129599A JP 50129599 A JP50129599 A JP 50129599A JP 2002504902 A JP2002504902 A JP 2002504902A
- Authority
- JP
- Japan
- Prior art keywords
- peg
- cytostatic
- encapsulation
- metabolites
- gadolinium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
- Y10S977/806—Virus-based particle with exterior chemical attachment
- Y10S977/808—Exterior attachment for targeting, e.g. drug targeting
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y10S977/907—Liposome
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/908—Mechanical repair performed/surgical
- Y10S977/911—Cancer cell destruction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/908—Mechanical repair performed/surgical
- Y10S977/912—Cancer cell repair
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/927—Diagnostic contrast agent
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.リポソームでカプセル化した細胞増殖抑制性物質及び/又はその代謝産物を ベースとする抗癌治療剤であって、 −PEG、免疫又は免疫/PEGリポソームでカプセル化した細胞増殖抑制性物質 及び/又はその代謝産物、 −分解性デンプン粒子及び/又はゼラチン及び/又はナノ粒子、 −ヨウ素、ガドリニウム又は磁鉄鉱含有造影剤 を含む薬剤。 2.細胞増殖抑制性物質及び/又はその代謝産物のカプセル封入が −SUV(Small unilamellar vesicles[小単層小胞])-PEG −LUV(Large unilamellar vesicles[大単層小胞])-PEG −REV(Reversed face evporation vesicle[逆面蒸発小胞])-PEG −MLV(Multilamellar vesicles[多重ラメラ小胞])-PEG で行われることを特徴とする請求項1に記載の薬剤。 3.細胞増殖抑制性物質及び/又はその代謝産物のカプセル封入が −抗Ki-67免疫-PEGリポソーム で行われることを特徴とする請求項1に記載の薬剤。 4.細胞増殖抑制性物質及び/又はその代謝産物のカプセル封入が −抗CEA-PEGリポソーム で行われることを特徴とする請求項1に記載の薬剤。 5.デンプン粒子が60-90nmの粒度を有することを特徴とする請求項1に記載の 薬剤。 6.吸収性ゼラチン粉末を使用することを特徴とする請求項1に記載の薬剤。 7.ナノ粒子としてPoloxamerの25%水溶液を使用することを特徴とする請求項 1に記載の薬剤。 8.下記の成分、即ち −細胞増殖抑制物質として5-フルオロウラシル −SUV-PEGによるカプセル封入 −デンプン粒子としてSpherex −造影剤としてガドリニウム-DTPA を特徴とする請求項1に記載の薬剤。 9.下記の成分、即ち −細胞増殖抑制物質として5-フルオロウリジン −SUV-PEGによるカプセル封入 −デンプン粒子としてSpherex −造影剤としてガドリニウム-DTPA を特徴とする請求項1に記載の薬剤。 10.下記の成分、即ち −細胞増殖抑制物質としてカルボプラチン −SUV-PEGによるカプセル封入 −デンプン粒子としてSphcrex又はGelfoam −造影剤としてガドリニウム-DTPA を特徴とする請求項1に記載の薬剤。 11.下記の成分、即ち −細胞増殖抑制物質として5'-ヘキサデシルリン酸5-フルオロウリジン −SUV-PEGによるカプセル封入 −デンプン粒子としてSpherex又はGelfoam −造影剤としてガドリニウム-DTPA を特徴とする請求項1に記載の薬剤。 12.動脈内、静脈内又は経口的適用による請求項1ないし6に記載の薬剤の使 用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19724796.2 | 1997-06-06 | ||
DE19724796A DE19724796A1 (de) | 1997-06-06 | 1997-06-06 | Mittel zur Antitumortherapie |
PCT/DE1998/001514 WO1998055103A1 (de) | 1997-06-06 | 1998-06-04 | Mittel zur antitumortherapie |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2002504902A true JP2002504902A (ja) | 2002-02-12 |
Family
ID=7832247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50129599A Pending JP2002504902A (ja) | 1997-06-06 | 1998-06-04 | 抗腫瘍治療剤 |
Country Status (6)
Country | Link |
---|---|
US (1) | US6207133B1 (ja) |
EP (1) | EP0989847B1 (ja) |
JP (1) | JP2002504902A (ja) |
AT (1) | ATE229796T1 (ja) |
DE (2) | DE19724796A1 (ja) |
WO (1) | WO1998055103A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012162577A (ja) * | 1999-12-09 | 2012-08-30 | A Nattermann & Co Gmbh | がん治療のための細胞増殖抑制剤及び電子受容体を含有する医薬製剤 |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE354377T1 (de) * | 1993-12-02 | 2007-03-15 | Max Delbrueck Centrum | Antitumormittel, enthaltend ein zytostatikum und ein kontrastmittel |
US6774278B1 (en) * | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
JP3907863B2 (ja) * | 1999-04-08 | 2007-04-18 | 独立行政法人科学技術振興機構 | アポトーシス抑制又は促進物質のスクリーニング方法 |
HUP0202299A3 (en) * | 1999-08-06 | 2004-05-28 | Max Delbrueck Centrum | Implantable active ingredient depot |
US6761877B2 (en) * | 2000-02-18 | 2004-07-13 | Biocrystal, Ltd. | Functionalized encapsulated fluorescent nanocrystals |
EP1427393A2 (de) * | 2000-05-02 | 2004-06-16 | Pharmacept GmbH | Wirkstoffhaltige liposome |
DE10115740A1 (de) | 2001-03-26 | 2002-10-02 | Ulrich Speck | Zubereitung für die Restenoseprophylaxe |
US7672704B2 (en) * | 2002-09-11 | 2010-03-02 | Duke University | Methods and compositions for blood pool identification, drug distribution quantification and drug release verification |
US7769423B2 (en) * | 2002-09-11 | 2010-08-03 | Duke University | MRI imageable liposomes for the evaluation of treatment efficacy, thermal distribution, and demonstration of dose painting |
DE10244847A1 (de) | 2002-09-20 | 2004-04-01 | Ulrich Prof. Dr. Speck | Medizinische Vorrichtung zur Arzneimittelabgabe |
US7462703B2 (en) * | 2003-01-31 | 2008-12-09 | Max-Delbruck-Centrum Fur Molekulare Medizin | Agent for gene transfer |
WO2004087105A1 (en) * | 2003-04-02 | 2004-10-14 | Celator Pharmaceuticals, Inc. | Combination formulations of platinum agents and fluoropyrimidines |
US20050152842A1 (en) * | 2003-12-24 | 2005-07-14 | Chun Li | Poly (L-glutamic acid) paramagnetic material complex and use as a biodegradable MRI contrast agent |
US20060280785A1 (en) * | 2004-08-11 | 2006-12-14 | Easterly Clay E | Biocidal materials for treatment against pathogens |
EA011594B1 (ru) * | 2004-12-30 | 2009-04-28 | Синвеншен Аг | Композиция, включающая агент, обеспечивающий сигнал, имплантируемый материал и лекарство |
ATE412691T1 (de) * | 2005-01-13 | 2008-11-15 | Cinv Ag | Kohlenstoffnanopartikel enthaltende verbundwerkstoffe |
KR20070102717A (ko) * | 2005-01-24 | 2007-10-19 | 신벤션 아게 | 금속 함유 복합 물질 |
AU2006224582A1 (en) * | 2005-03-18 | 2006-09-21 | Cinvention Ag | Process for the preparation of porous sintered metal materials |
CA2603437A1 (en) * | 2005-04-01 | 2006-10-12 | The Board Of Regents Of The University Of Texas System | Poly(peptide) as a chelator: methods of manufacture and uses |
CN101238166A (zh) * | 2005-07-01 | 2008-08-06 | 金文申有限公司 | 制备多孔网状复合材料的方法 |
BRPI0612602A2 (pt) * | 2005-07-01 | 2010-11-23 | Cinv Ag | dispositivos médicos compreendendo um material compósito reticulado |
JP5377965B2 (ja) | 2005-09-09 | 2013-12-25 | ジョージア ステート ユニバーシティ リサーチ ファウンデーション、インコーポレイテッド | 標的化された造影剤および造影剤を標的化するための方法 |
WO2007045616A1 (en) * | 2005-10-18 | 2007-04-26 | Cinvention Ag | Thermoset particles and methods for production thereof |
KR101443926B1 (ko) | 2006-06-15 | 2014-10-02 | 마이크로벤션, 인코포레이티드 | 팽창성 중합체로 제조된 색전술용 장치 |
US8243877B2 (en) * | 2006-09-12 | 2012-08-14 | Weil Michael D | Dual-use radiation system |
EP2231215B1 (en) | 2007-12-21 | 2019-01-30 | MicroVention, Inc. | Hydrogel filaments for biomedical uses |
EP2257316B1 (en) * | 2008-04-02 | 2018-11-07 | Georgia State University Research Foundation, Inc. | Contrast agents, methods for preparing contrast agents, and methods of imaging |
US9993252B2 (en) | 2009-10-26 | 2018-06-12 | Microvention, Inc. | Embolization device constructed from expansile polymer |
WO2012145431A2 (en) | 2011-04-18 | 2012-10-26 | Microvention, Inc. | Embolic devices |
WO2015167752A1 (en) | 2014-04-29 | 2015-11-05 | Microvention, Inc. | Polymers including active agents |
WO2016201250A1 (en) | 2015-06-11 | 2016-12-15 | Microvention, Inc. | Expansile device for implantation |
CN115364114B (zh) * | 2021-05-21 | 2023-12-01 | 武汉科福新药有限责任公司 | 羧基麦芽糖铁药用组合物及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996018421A1 (de) * | 1993-12-02 | 1996-06-20 | Max-Delbrück-Centrum für Molekulare Medizin | Antitumormittel, enthaltend ein zytostatikum und ein kontrastmittel |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5387410A (en) * | 1983-03-18 | 1995-02-07 | Mallinckrodt, Inc. | Method for enhancing magnetic resonance with compositions containing paramagnetic elements carried by liposomes |
DE3336583A1 (de) * | 1983-09-26 | 1985-04-25 | Udo Dr. 8400 Regensburg Ehrenfeld | Erzeugnis zur diagnose und therapie von malignen tumoren |
US5213788A (en) * | 1988-09-29 | 1993-05-25 | Ranney David F | Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5705187A (en) * | 1989-12-22 | 1998-01-06 | Imarx Pharmaceutical Corp. | Compositions of lipids and stabilizing materials |
US5215680A (en) * | 1990-07-10 | 1993-06-01 | Cavitation-Control Technology, Inc. | Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles |
WO1992021017A1 (en) * | 1991-05-23 | 1992-11-26 | Unger Evan C | Liposoluble compounds for magnetic resonance imaging |
US5620703A (en) * | 1991-10-11 | 1997-04-15 | Max-Delbruck-Centrum Fur Molekulare Medizin | Stimulating hematopoietic activity with carboplatin or lobaplatin |
EP0654973A4 (en) * | 1992-07-21 | 1995-08-09 | Gen Hospital Corp | LYPHATIC TISSUE DRUG ADMINISTRATION SYSTEM. |
US5512294A (en) * | 1994-08-05 | 1996-04-30 | Li; King C. | Targeted polymerized liposome contrast agents |
WO1998007409A1 (en) * | 1996-08-23 | 1998-02-26 | Sequus Pharmaceuticals, Inc. | Liposomes containing a cisplatin compound |
WO1998044910A1 (en) * | 1997-04-09 | 1998-10-15 | Philipp Lang | NEW TECHNIQUE TO MONITOR DRUG DELIVERY NONINVASIVELY $i(IN VIVO) |
-
1997
- 1997-06-06 DE DE19724796A patent/DE19724796A1/de not_active Withdrawn
-
1998
- 1998-06-04 DE DE59806734T patent/DE59806734D1/de not_active Expired - Lifetime
- 1998-06-04 US US09/445,292 patent/US6207133B1/en not_active Expired - Lifetime
- 1998-06-04 EP EP98936092A patent/EP0989847B1/de not_active Expired - Lifetime
- 1998-06-04 AT AT98936092T patent/ATE229796T1/de not_active IP Right Cessation
- 1998-06-04 WO PCT/DE1998/001514 patent/WO1998055103A1/de active IP Right Grant
- 1998-06-04 JP JP50129599A patent/JP2002504902A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996018421A1 (de) * | 1993-12-02 | 1996-06-20 | Max-Delbrück-Centrum für Molekulare Medizin | Antitumormittel, enthaltend ein zytostatikum und ein kontrastmittel |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012162577A (ja) * | 1999-12-09 | 2012-08-30 | A Nattermann & Co Gmbh | がん治療のための細胞増殖抑制剤及び電子受容体を含有する医薬製剤 |
Also Published As
Publication number | Publication date |
---|---|
EP0989847A1 (de) | 2000-04-05 |
EP0989847B1 (de) | 2002-12-18 |
ATE229796T1 (de) | 2003-01-15 |
DE19724796A1 (de) | 1998-12-10 |
WO1998055103A9 (de) | 1999-04-08 |
US6207133B1 (en) | 2001-03-27 |
WO1998055103A1 (de) | 1998-12-10 |
DE59806734D1 (de) | 2003-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002504902A (ja) | 抗腫瘍治療剤 | |
JP3270478B2 (ja) | 強化されたドラッグ・デリバリーのためのスフィンゴソーム | |
JP2968588B2 (ja) | Nmr画像形成のための粒子及び製造方法 | |
Harrington et al. | Liposomes as vehicles for targeted therapy of cancer. Part 1: preclinical development | |
CA2067178C (en) | Solid tumor treatment method and composition | |
AU2005284909B2 (en) | Delivering iron to an animal | |
JPS63233915A (ja) | 両親媒性物質会合活性成分を取り込んだ運搬担体 | |
JP2006514016A (ja) | リポソーム処方物 | |
JP2004511426A5 (ja) | ||
JPH0761947B2 (ja) | リン脂質ミセル粒子に被包されたアントラサイクリン抗腫瘍薬 | |
Le et al. | Long-circulating gadolinium-encapsulated liposomes for potential application in tumor neutron capture therapy | |
EP0358719B1 (en) | Liposome compositions of anthracycline derivatives | |
van der Veen et al. | Biodistribution and tumor localization of stealth liposomal tumor necrosis factor‐α in soft tissue sarcoma bearing rats | |
JP2677576B2 (ja) | 非水溶性の有効成分のためのリン脂質輪送ビヒクル | |
US6479033B1 (en) | Antitumor cystostatic and contrast agent | |
JP2005534718A (ja) | カチオンキャリヤー系において診断化合物および治療化合物を安定化させる新規方法 | |
US20020110601A1 (en) | Antineoplastic platinum therapeutic method and composition | |
US20030124180A1 (en) | Liposomes containing active substances | |
Mori et al. | In vivo antitumor activity of cis-bis-neodecanoato-trans-R, Rl, 2-diaminocyclohexane platinum (II) formulated in long-circulating liposomes | |
JP2005511578A (ja) | リポソームに封入されたタキソールを含む経口投与用の医薬製剤 | |
Chandraprakash et al. | Effect of niosome encapsulation of methotrexate, macrophage activation on tissue distribution of methotrexate and tumor size | |
CN116648252A (zh) | 微脂体组合物及其制备方法 | |
WO2020254633A1 (en) | Liposomal doxorubicin formulation, method for producing a liposomal doxorubicin formulation and use of a liposomal doxorubicin formulation as a medicament | |
WO2003022250A2 (en) | Unilamellar vesicles stabilized with short chain hydrophilic polymers | |
RU2706427C1 (ru) | Способ лечения онкологических заболеваний с помощью инъекций лекарственного препарата |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050603 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080909 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081209 Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081210 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090126 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090206 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090316 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090309 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090707 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091001 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100107 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100803 |